NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company • Johnson and Johnson (amivantamab) Patient/carer groups • Asthma and Lung UK • Black Health Agency for Equality • Cancer Black Care • Cancer Equality • Cancer52 • EGFR Positive UK • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • NARA – The Breathing Charity • Oncogene-Driven Lung Cancer Patient Alliance UK • Roy Castle Lung Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • UK Lung Cancer Coalition Healthcare professional groups • Association for Respiratory Technology and Physiology • Association of Anaesthetists • Association of Cancer Physicians • Association of Respiratory Nurse Specialists • Association of Surgeons of Great Britain and Ireland • British Geriatrics Society • British Institute of Radiology • British Oncology Pharmacy	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health – Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee Comparator companies • Amarox (erlotinib) • Aspire pharma (pemetrexed) • AstraZeneca (gefitinib, osimertinib) • Boehringer Ingelheim (afatinib) • Bristol Myers Squibb (paclitaxel) • Cipla EU (gefitinib) • Eli Lilly and company (pemetrexed) • Genus pharmaceuticals (pemetrexed, gefitinib) • Glenmark Pharmaceutical (erlotinib) • Hospira UK (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) • Medac GmbH (vinorelbine) • Merck, Sharp & Dohme

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Association • British Psychosocial Oncology Society • British Rhinological Society • British Society of Interventional Radiology • British Thoracic Oncology Group • British Thoracic Society • British Transplantation Society • Cancer Research UK • ILD-IN: Interstitial Lung Diseases Interdisciplinary Network • Lung Cancer and Mesothelioma Clinical Expert Group • Lung Cancer Nursing UK • National Heart and Lung Institute • NHS Blood and Transplant • Primary Care Respiratory Society • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <u>Others</u> • Department of Health and Social Care • NHS England	(pembrolizumab) • Mylan (erlotinib) • Pfizer (pemetrexed, dacomitinib) • Pierre Fabre (vinorelbine) • Roche (atezolizumab, erlotinib) • Sandoz (cisplatin, docetaxel, pemetrexed, erlotinib, gefitinib) • Seacross pharmaceuticals (docetaxel, paclitaxel, pemetrexed) • Sun Pharmaceuticals (gemcitabine, pemetrexed) • Synchrony Pharma (gemcitabine) • Teva UK (paclitaxel) • Zentiva (pemetrexed, erlotinib) <u>Relevant research groups</u> • British Association for Lung Research • Cochrane Airways Group • Cochrane Lung Cancer Group • Cochrane UK • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Institute for Health Research <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient

organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non-company consultees are invited to submit statements relevant to the group they are representing.

